944 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
PFE Pfizer, Inc. $43.01 $252.13B Sell
Article Searches
Here Are the Key Takeaways From J&J's Q1 Earnings Report http://www.zacks.com/stock/news/386860/here-are-the-key-takeaways-from-jjs-q1-earnings-report?cid=CS-ZC-FT-386860 Apr 18, 2019 - Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
Wave Life Sciences Plunges After DMD Study Data Readout http://www.zacks.com/stock/news/386326/wave-life-sciences-plunges-after-dmd-study-data-readout?cid=CS-ZC-FT-386326 Apr 17, 2019 - Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.
J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View http://www.zacks.com/stock/news/382057/jj-jnj-beats-on-q1-earnings-ups-2019-sales-growth-view?cid=CS-ZC-FT-382057 Apr 16, 2019 - J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-ZC-FT-380671 Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
These 3 Value Stocks Are Absurdly Cheap Right Now https://www.fool.com/investing/2019/04/09/these-3-value-stocks-are-absurdly-cheap-right-now.aspx?source=iedfolrf0000001 Apr 09, 2019 - Good bargains are hard to find in today's market. Here are a few overlooked stocks for you to capitalize on.
Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients http://www.zacks.com/stock/news/372924/glaxos-dovato-gets-fda-nod-for-treatment-naive-hiv-patients?cid=CS-ZC-FT-372924 Apr 09, 2019 - Glaxo's (GSK) ViiV Healthcare gets FDA approval for a single-tablet two-drug regimen (2DR), Dovato for treatment naive HIV- 1 adults.
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men http://www.zacks.com/stock/news/371759/pfizers-ibrance-gets-fda-approval-for-breast-cancer-in-men?cid=CS-ZC-FT-371759 Apr 06, 2019 - Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men http://www.zacks.com/stock/news/371728/pfizers-ibrance-gets-fda-approval-for-breast-cancer-in-men?cid=CS-ZC-FT-371728 Apr 05, 2019 - Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU http://www.zacks.com/stock/news/371503/pharma-stock-roundup-nvs-inks-immunology-deal-pfe-teva-get-drug-approvals-in-eu?cid=CS-ZC-FT-371503 Apr 05, 2019 - Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Dow 30 Stock Roundup: WBA Q2 Earnings Disappoint, PFE Lung Cancer Drug Gets EU Approval http://www.zacks.com/stock/news/371316/dow-30-stock-roundup-wba-q2-earnings-disappoint-pfe-lung-cancer-drug-gets-eu-approval?cid=CS-ZC-FT-371316 Apr 05, 2019 - The index notched up another week of gains riding on optimism over the increasing likelihood of a U.S.-China trade deal.

Pages: 123456...95

Page 1>